Comparative molecular analyses of BRAF-V600E mutant tumors: Colorectal cancers (CRC) vs. melanomas | Caris Life Sciences
Portal
Order

MI Cancer Seek™ is now available for clinical ordering. Learn more.

Home / Research / Publications / Comparative molecular analyses of BRAF-V600E mutant tumors: Colorectal cancers (CRC) vs. melanomas

Publications

Back

Comparative molecular analyses of BRAF-V600E mutant tumors: Colorectal cancers (CRC) vs. melanomas

– Caris Life Sciences

Poster

Background

Little is known about the molecular characteristics of BRAF mutant (mt) CRC. It is unknown whether BRAF mt CRC have molecular and biological profile similar to BRAF mutant melanomas (Mel).

Download Publication

Discover
More

  • Loss of O6-Methylguanine-DNA Methyltransferase Protein Expression by Immunohistochemistry Is Associated With Response to Capecitabine and Temozolomide in Neuroendocrine Neoplasms

    – Caris Life Sciences

    Manuscript

    Abstract Background A recent prospective phase II study (ECOG-ACRIN E2211) demonstrated that MGMT deficiency was associated with a significant response to capecitabine and temozolomide (CAPTEM)… […]

  • Clinical and Molecular Characterization of FAP and SPP1 in Colorectal Cancer (CRC), CALGB (Alliance)/SWOG 80405 and Real-world Data

    – Caris Life Sciences

    Poster

    Background […]
Learn More

Ready to Get Started on the Journey?

Name(Required)